Constant Therapy, a Boston, MA-based provider of science-based, customized brain rehabilitation apps, raised $2m in Series A funding.
The round was led by Golden Seeds with participation from Kapor Capital, Launchpad Venture Group, Pond Capital and Community Health Network of Connecticut.
The company intends to use the funds to expand the scientific research, data, marketing and development behind its product.
Founded in 2013 by Boston University professor Swathi Kiran, who was head of the Aphasia Research Laboratory and led by Keith Cooper, CEO, Constant Therapy provides mobile applications for continuous and customized therapy to people with speech, language, cognition, memory and learning disorders.
The company provides a comprehensive set of tools for traumatic brain injury (TBI) and stroke survivors and for people with aphasia or dementia, or children who need special education and care due to learning disabilities.
Constant Therapy’s library of therapeutic tools today includes 65 science-based therapy categories and more than 60,000 exercises.
Healthcare organizations that use Constant Therapy include Spaulding Rehabilitation Network, the Stroke Comeback Center and The MossRehab Aphasia Center.